fbpx

BAP1 Gene Mutation Linked to Increased Mesothelioma Survival

Share Button

The median survival for the BAP1 mesothelioma patients was five years, as compared with less than one year for the median survival for those patients without the BAP1 gene.

Image result for image of mesothelioma

Mesothelioma is a complicated cancer. The saying “the devil is in the details” is especially true for mesothelioma patients. If you have the BAP1 gene mutation you will live, on average, more than five years. And you were probably told that you only had a year or two…Conversely, if your cancer cells exhibit an enzyme called CD 10, your prognosis will change again.

Couple this info with those complementary and integrative therapies that also increase overall survival or reduce the toxicity of conventional therapies and you may climb out of the “incurable” hole that your onc put you in.

I too was told that my cancer, multiple myeloma was incurable and had a 3-5 year life expectancy…I was first diagnosed in 2/94.

For more information on mesothelioma scroll down the page, post your question or comment and I will reply ASAP.

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

BAP1 Mutation Linked to “Seven-Fold” Increased Survival in Mesothelioma Patients

“When comparing the data, the researchers found the “actuarial median survival” for the BAP1-meso patients was five years, as compared with less than one year for the median survival for those patients who did not carry the BAP1 gene. And interestingly, patients with peritoneal meso, meso of the lining of the abdomen, or with a second malignancy in addition to mesothelioma “survived for a longer time compared to patients who only had pleural meso, or meso patients without a second malignancy.”

The researchers at first thought that while it has been shown that female mesothelioma patients have a longer survival than their male counterparts, their findings would further prove this out. What they found instead was that female BAP1 mesothelioma patients had a four-times better survival, whereas the male BAP1 patients had a nine-times five year increase in survival. This finding discounted the theory that gender played a role in survival…”

Leave a Comment:

1 comment
Add Your Reply